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Intrastriatal transplantation of fetal human ventral mesencephalic dopaminergic neurons
is an experimental therapy for patients suffering from Parkinson’s disease. The success
of this approach depends on several host brain parameters including neurotrophic
factors and growth inhibitors that guide survival and integration of transplanted
neurons. While the potential of neurotrophic factors has been extensively investigated,
repression of growth inhibitors has been neglected, despite the significant effects
reported in various CNS injury models. Recently, we demonstrated that infusion of
neutralizing antibodies against Nogo-A into the lateral ventricles of hemi-parkinsonian
rats significantly enhanced graft function. Since the Nogo-receptor 1 also interacts
with other neurite growth inhibitors, we investigated whether a direct antagonization
of the receptor would result in more robust effects. Therefore, rats with unilateral
striatal 6-hydroxydopamine lesions were grafted with ventral mesencephalic tissue in
combination with intraventricular infusions of the Nogo-receptor 1 antagonist NEP1-40.
Transplanted rats receiving saline infusions served as controls. To test whether NEP1-40
treatment alone affects the remaining dopaminergic striatal fibers, rats with unilateral
striatal 6-hydroxydopamine lesions were infused with NEP1-40 or saline without
receiving a transplant. Motor behavior was assessed prior to the lesion as well as
prior and 1, 3, and 5 weeks after the transplantations. At the end of the experimental
period the number of graft-derived dopaminergic fibers growing into the host brain,
the number of surviving dopaminergic neurons and graft volume were analyzed. In rats
without a transplant, the density of dopaminergic fibers in the striatum was analyzed.
We detected that NEP1-40 treatment significantly enhanced graft-derived dopaminergic
fiber outgrowth as compared to controls while no effects were detected for graft volume
and survival of grafted dopaminergic neurons. Notably, the enhanced dopaminergic
fiber outgrowth was not sufficient to improve the functional recovery as compared to
controls. Moreover, NEP1-40 infusions in hemi-parkinsonian rats without a transplant
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did not result in enhanced striatal dopaminergic fiber densities and consequently did
not improve behavior. In sum, our findings demonstrate that antagonization of
the Nogo-receptor 1 has the capacity to support the engraftment of transplanted
mesencephalic tissue in an animal model of Parkinson’s disease.
Keywords: Parkinson’s disease, Nogo-receptor 1, cell transplantation, dopaminergic neurons, behavior, rat
INTRODUCTION
Parkinson’s disease (PD) is a neurodegenerative disease mainly
characterized by progressively degenerating dopaminergic
neurons in the substantia nigra pars compacta. The resulting
lack of dopaminergic innervation of the striatum and consequent
loss of dopamine leads to severe motor symptoms. Cell
replacement strategies, i.e., transplantation of human fetal
ventral mesencephalic (VM) tissue into the caudate and
putamen of patients, that intend to restore the lost dopamine
in the striatum, can result in considerable long-term motor
improvement up to several years after transplantation (Yasuhara
et al., 2006; Hallett et al., 2014; Kefalopoulou et al., 2014;
Pantcheva et al., 2015) and are thus a promising experimental
approach to treat PD (Bjorklund et al., 2003; Ourednik
and Ourednik, 2005; Piquet et al., 2012). For a successful
outcome, it is important to assure the survival of grafted
dopaminergic cells and their functional integration into the
host brain (Emgard et al., 1999; Karlsson et al., 2000; Rath
et al., 2013), a process in which the host microenvironment
plays a crucial role (Ourednik and Ourednik, 2005; Alsberg
et al., 2006; Stefanova et al., 2009; Akbik et al., 2012). The
microenvironment consists of the totality of signals induced
by local neurotrophic and neurite growth inhibiting factors.
The significant improvement in engraftment of VM tissue by
administering neurotrophic factors, such as glial cell line-derived
neurotrophic factor, brain-derived neurotrophic factor, and
neurotrophin 4/5 into the host striatum has been demonstrated
years ago (Haque et al., 1996; Rosenblad et al., 1996; Sinclair
et al., 1996; Yurek et al., 1996; Yurek, 1998; Espejo et al.,
2000; Chaturvedi et al., 2006; Tatard et al., 2007; Thompson
et al., 2009). While inhibition of Nogo-A signaling, one of the
most potent neurite growth inhibitor in the central nervous
system (CNS), has been successfully implemented in various
models of CNS injuries (Gonzenbach and Schwab, 2008;
Schwab and Strittmatter, 2014), it has so far been largely
neglected in studies of cell transplantation approaches for PD.
We have recently demonstrated that intraventricular infusion
of neutralizing anti-Nogo-A antibodies enhanced survival of
grafted dopaminergic neurons and significantly promoted their
fiber outgrowth, resulting in an improved functional recovery
of the hemi-parkinsonian rats (Seiler et al., 2016). Nogo-A
can bind to the Nogo-receptor 1 (NgR1), which then interacts
with the leucine rich repeat neuronal protein (LINGO-1) and
the low affinity nerve growth factor receptor (p75) and/or the
tumor necrosis family member LIMK (TROY) before activating
the Rho/ROCK pathway (Schmandke et al., 2014). We and
others have shown, that both the neutralization of Nogo-A
and the antagonization of the NgR1 complex improve the
survival and morphology of dopaminergic neurons. In fact,
deletion or antagonization of LINGO-1 enhanced the survival
of dopaminergic neurons in an in vitro and mouse model
of PD (Inoue et al., 2007). Moreover, we could show that
antagonization of NgR1 by the peptide NEP1-40 significantly
improved the survival of dopaminergic neurons and their
morphological complexity in fetal primary VM cultures
(Seiler et al., 2013). Based on these observations, we aimed
at investigating whether NgR1 antagonization by NEP1-40
improves survival and integration of grafted dopaminergic
neurons and functional recovery in a hemi-parkinsonian rat
model.
MATERIALS AND METHODS
Animals
Adult female Wistar rats (Janvierlabs, France) were housed at
12 h light dark cycle with food and water ad libitum. For
the preparation of the transplants, time-pregnant Wistar dams
were purchased from Janvierlabs (France). All experiments were
carried out in the light phase and in accordance with the
guidelines of the Animal Research Ethics Committee of the
Canton Berne, Switzerland, and the University of Bern Animal
Care and Use Committee, Switzerland.
Experimental Design
The experimental design is schematically depicted in Figure 1
and was planned similar to our previous study (Seiler et al.,
2016). In the first experimental setup, the hemi-parkinsonian rats
received a transplant and a mini-osmotic pump releasing either
saline or NEP1-40 into the right lateral ventricles (Figure 1A).
In the second experimental setup, hemi-parkinsonian rats
received only mini-osmotic pumps releasing either saline or
NEP1-40 into the right lateral ventricles (Figure 1B). To create
hemi-parkinsonian rats, 6-hydroxydopamine (6-OHDA) was
injected into the right striatum. Six week after the lesions, fetal
rat VM tissue was transplanted into the right striatum. In the
same surgical procedure, mini-osmotic pumps that continuously
infused either saline or NEP1-40 into the right lateral ventricle
were implanted (Figure 1A). Six weeks after the transplantations
rats were perfused and their brains prepared for histological
analyses. In these rats asymmetrical forelimb use was assessed by
means of the cylinder test before (baseline) and 5 weeks after the
lesions (lesioned) and 1, 3, and 5 weeks after the transplantations
(Figure 1A). In the rats implanted with mini-osmotic pumps only
asymmetrical forelimb use was assessed with the cylinder test
before the lesion (baseline), 5 weeks after the lesion (lesioned) and
5 weeks after the pump implantation (Figure 1B).
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FIGURE 1 | Experimental design of the study. The experiments were conducted in two experimental set ups. In the first experiment hemi-parkinsonian rats
received a transplant and a mini-osmotic pump (A) and in the second experiment hemi-parkinsonian rats received only a mini-osmotic pump and no transplant (B).
The neurotoxin 6-hydroxydopamine was injected unilateral into the right striatum of rats (lesion) and 6 weeks later the rats of experimental setup 1 received a
transplant of two ventral mesencephalic free-floating roller tube cultures (Tx). Mini-osmotic pumps were implanted into all hemi-parkinsonian rats, releasing either
saline or NEP1-40 over a period of 2 weeks into the lateral ventricles (black box). Six weeks after the surgeries rats were transcardially perfused and the brains
removed for histological analyses. The cylinder test was assessed in the rats of both the experimental groups, 1 week before the lesion (behavior baseline) and
1 week prior to surgery (behavior lesioned). In the experimental setup 1 behavioral analyzes were performed 1, 3, and 5 weeks post transplantation (behavior
1Wp.T.; behavior 3Wp.T.; behavior 5Wp.T.). In the experimental setup 2 behavior was evaluated 5 weeks after the surgery (behavior 5Wp.S.).
Parkinson’s Disease Rat Model
Female Wistar rats (200–270 g; Janvierlabs, France) were
anesthetized with Isoflurane (75% N2O, 20% O2, 4.5–5%)
followed by an intraperitoneal (i.p.) injection of Narketan
(75 mg/kg; Vétoquind AG, Ittigen, CH) and Xylazine (5 mg/kg;
Vétoquind AG, Ittigen, CH). Buprenorphine (0.5 mg/kg; Reckitt
Benckiser AG, Wallisellen) was subcutaneously (s.c.) injected
30 min before the surgical intervention. Under deep anesthesia
the rats were placed on a heating pad and fixed in a stereoscopic
frame (Stoelting Co.). Through a small burr hole in the skull
4 µl of 6-OHDA (32 mM 6-OHDA; H116 Sigma–Aldrich
Chemie GmbH) were injected into the right striatum according
to the following coordinates in relation to bregma (Paxinos
Watson rat brain atlas): anterior 1.0 mm, lateral 3.0 mm
and 5.0 mm ventral to the dura, the incisor bar was set at
0.0 mm. The injection rate was 1 µl/min. The syringe was
left in place for additional 4 min before slowly retracting the
needle.
Preparation of Transplants
The tissues for the transplantations were organotypic fetal rat
free-floating roller tube cultures prepared from embryonic day 14
(E14) VM as described previously (Andereggen et al., 2009; Seiler
et al., 2016). In brief, time-pregnant Wistar rats were anesthetized
with Isoflurane (75% N2O, 20% O2, 4.5–5%) followed by an i.p.
injection of Narketan (120 mg/kg) and Xylazine (20 mg/kg) and
their fetuses removed by cesarean section. The VM was separated
from the brain under a stereoscopic microscope and cut into four
equally sized pieced that correspond to two rostral and two caudal
portions. Each piece was placed into a gas-permeable conical
plastic tube (Falcon) filled with 1 ml of culture medium consisting
of 55% DMEM, 32.5% Hank’s balanced salt solution (HBSS;
Gibco), 0.3% glucose, 10% fetal calf serum (FCS; Gibco) and
1% 0.01 M HEPES (Merck) as well as antibiotics/antimycotics
(No. 061-052 40 D; Gibco). Each tube was positioned in a
rotating roller drum that was placed in an incubator at 37◦C
in a 5% CO2 atmosphere as described in detail previously
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(Spenger et al., 1994). The VM tissue was grown for 7 days and
the medium was changed after 2 and 5 days in vitro.
Transplantation and Pump Implantation
Six weeks after the 6-OHDA lesions, rats were anesthetized
with Isoflurane (75% N2O, 20% O2, 4.5–5%) followed by an
i.p. injection of Narketan (75 mg/kg; Vétoquinol AG, Ittigen,
CH) and Xylazine (5 mg/kg; Vétoquinol AG, Ittigen, CH).
Buprenorphine (0.5 mg/kg; Reckitt Benckiser AG, Wallisellen)
was s.c. injected 30 min before the surgical intervention. In
deep anesthesia the rats were put on a heating pad and
mounted on a stereoscopic frame. Half a ventral mesencephalon
consisting of one rostral and one caudal part of one embryo
was transplanted into the right striatum. This guaranteed
approximately equal amounts of dopaminergic neurons per
graft. The following coordinates in relation to bregma (Paxinos
Watson rat brain atlas) were used: anterior 1.0 mm, lateral
2.7 mm and 4.5 mm ventral to the dura, the incisor bar
was set at 0.0 mm. Next, mini-osmotic pumps (2 ml2, Alzet
osmotic pumps, DURECT Corporation ALZET Osmotic Pumps)
pre-filled with saline or NEP1-40 (75 µg/kg/day) (GrandPre
et al., 2002) were implanted under the skin of all the rats
and the cannulas were subcutaneously connected to the skull
and placed into the right ventricles (Alzet brain infusion kit2)
according to the following coordinates in relation to bregma
(Paxinos Watson rat brain atlas): posterior 0.8 mm, lateral
1.6 mm and 3.5 mm ventral to the dura, the incisor bar was
set at 0.0 mm. The substances were administered by the mini-
osmotic pumps continuously over the subsequent 2 weeks with
a flow rat of 5 µg/h. The animals were randomly assigned to
the two treatment groups (saline n = 6; NEP1-40 n = 7). Rats
from the non-grafted groups (experimental setup 2) experienced
the same mini-osmotic pump surgeries (saline n = 7; NEP1-40,
n = 7). Animals were let to recover for 1 week after the
surgery.
Behavior Test Series
The cylinder test is a reliable measure to assess the asymmetry
in forelimb use as observed after a unilateral lesion of the
dopaminergic nigro-striatal pathway (Brooks and Dunnett, 2009;
Schaar et al., 2010) and was evaluated as previously described
(Seiler et al., 2016). In brief the rats were placed in a transparent
cylinder (diameter 30 cm and height 41 cm) with mirrors
placed around it to allow a 360 degree view on the cylinder
walls. The 10 min video recordings of the rat’s behavior were
analyzed by a researched blinded to the treatment groups by
counting the number of wall touches with the left, the right
and both paws together. To discriminate between a meaningful
physiological movement and an accidental touch, only wall
contacts by which the rat supported its body weight on the
forelimb with extended digits were counted. One animal in
the control group had to be excluded from the analysis as it
did not touch the wall at all after the lesion. The percentage
of left wall touches are calculated according to the formula:
[(left + 1/2 of both paw touches)/(left + right + both paw
touches)] ∗ 100 as previously described (Boix et al., 2015; Seiler
et al., 2016).
Perfusions
Six weeks after the transplantation, rats were anesthetized with
Isoflurane (75% N2O, 20% O2, 4.5–5%) followed by an i.p.
injection of Narketan (75 mg/kg) and Xylazine (5 mg/kg).
Fentanyl (0.005 mg/kg, Janssen-AG, Zug, CH) was i.p. injected
just prior to opening the thorax and the rats were perfused with
200 ml ice cold 0.1 M phosphate buffer saline (PBS, pH 7.4)
containing heparin (1000 I. E./100 ml, NOVO Nordisk) followed
by 250 ml 4% paraformaldehyde in 0.1 M PBS. The brains were
removed from the skull and placed in 4% paraformaldehyde
overnight and thereafter cryoprotected in 10% sucrose-PBS
solution.
Immunohistochemistry
Immunohistochemistry was performed as described previously
(Seiler et al., 2016). The brains were cut at 30 µm on
a cryostat (Leica CM 1900) and mounted on Superfrost
slides (Thermo Scientific). Sections were heated in citrate
buffer for 30 min and blocked with 10% horse serum in
0.1% Triton-PBS. Primary and secondary antibodies were
incubated in a 0.1% Triton-PBS solution containing 2.5% horse
serum. Slides were incubated with the mouse monoclonal
anti-tyrosine hydroxylase (TH; 1:1000, Millipore) overnight.
After PBS washes, sections were incubated for 2 h with the
secondary biotinylated anti-mouse IgG antibody (1:200, Vector
Laboratories) and the endogenous peroxidase blocked with a
solution of 10% methanol and 3% hydrogen peroxide in PBS.
Thereafter, the slides were incubated with an avidin-biotin-
complex (7 µl/ml; Vectastain ABC-Peroxidase KIT, Vector Labs)
for 1 h and specifically bound antibodies were visualized with
a metal-enhanced 3,3′-diaminobenzidine substrate kit (Pierce,
34002, Life Technologies). The sections were dehydrated in
alcohol, cleared in xylene and mounted in Eukitt (O. Kindler
GmbH, Freiburg, Germany).
Histological Analyses
All analyses were done by a researcher blinded to the treatment
groups.
Estimation of TH Positive Cells in the SNc
The estimation of the extent of the lesion was done as
described previously (Tronci et al., 2012; Seiler et al., 2016).
In brief, brain sections of each rat were chosen that match the
following coordinates in relation to bregma (Paxinos Watson
rat brain atlas): posterior 4.8 mm (three sections analyzed,
range 4.7–4.9 mm), 5.3 mm (three sections analyzed, range
5.2–5.4 mm), and 5.8 mm (three sections analyzed, range
5.7–5.9 mm). A light microscope equipped with a motorized
stage and a video camera connected to a PC was used for
counting. After delineation of the SNc with a 1× objective,
the CAST system (Visiopharm) generated an unbiased counting
frame with the 40× objective within the delineated SNc area.
Only TH positive cells with a clearly stained cell body that were
within the counting frame were counted. Data are expressed as
percentage of TH positive cells on the lesioned side as compared
to the number of TH positive neurons on the unlesioned side.
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FIGURE 2 | Asymmetrical forelimb use of saline or NEP1-40 treated rats assessed with the cylinder test. The contralateral forelimb use (left paw use) is
shown before (baseline) and after the 6-hydroxydopamine lesions as well as 1 (1Wp.T.; A), 3 (3Wp.T.; B) and 5 weeks post transplantation (5Wp.T.; C) in the
experimental setup 1. The lesions resulted in a significantly reduced number of wall touches with the left paw as compared to baseline levels (A–C). Animals
exposed to NEP1-40 treatment gradually improved the asymmetrical forelimb use over the 5 weeks period (B,C), however, did not reach baseline level (A–C). While
an overall similar outcome was observed for the saline treated group at 5Wp.T. these animals did not perform significantly better than at the post-lesion time point
(C). In the experimental setup 2, no behavioral recovery was found 5 weeks after pump implantation (5Wp.S) in both groups (D). Data are given as mean + SEM and
expressed as percentage of left paw use. ∗p < 0.05 vs. corresponding baselines, #p < 0.05 vs. corresponding lesion levels.
Estimation of the Graft Volume
Every third section containing a graft was selected to determine
the size of the graft as previously reported (Andereggen et al.,
2009; Seiler et al., 2016). In brief, an Olympus microscope
(Olympus DP72) equipped a digital camera and connected
to a PC with a calibrated neuron tracing software (CellSens
Dimension, Olympus) was used to trace the graft boundaries.
Thereafter, an automated computation integrated the areas to
yield the graft volume. Graft volume in control animals was
0.21± 0.03 mm3 (mean± SEM; n= 6).
Estimation of the TH Positive Fibers Growing into the
Host Brain
Every third section containing a graft was selected to determine
the number of TH positive fibers growing 100 µm into the host
brain as previously described (Seiler et al., 2016). In brief, an
Olympus microscope (Olympus DP72) equipped a digital camera
and connected to a PC with a calibrated neuron tracing software
(CellSens Dimension, Olympus) was used to draw a virtual line
100 µm from the graft boundary with a length of 300 µm. TH
positive fibers originating in the graft were followed up to this
virtual line and counted if they crossed this line. The counts were
done at four sites, i.e., medial, lateral, dorsal, and ventral from
the boarder of the graft using a 10× objective and verified with a
40× objective. Number of TH positive fibers in control animals
were 5.5 ± 1.1, 7.7 ± 0.4, 4.6 ± 0.9, and 5.8 ± 1.1 crossing the
virtual line at the medial, lateral, dorsal and ventral sites of the
graft, respectively (mean± SEM; n= 6).
Estimation of the TH Positive Cells in the Graft
Every third section containing a graft was selected to determine
the number of TH positive cells in the graft using the optical
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FIGURE 3 | Effects of intra-ventricular infusion of saline or NEP1-40 on
graft volumes. Representative photomicrographs of intrastriatal grafts
treated with either saline (A) or NEP1-40 (B) stained for tyrosine hydroxylase.
The graft boarder is highlighted with a dashed black line. Scale bar: 100 µm.
No difference in graft volume was detected between the two treatment
groups, as shown in the bar graph (C). Data are given as mean + SEM and
are presented as percentage of saline.
fractionators design as described by West et al. (1991), Kelsen
et al. (2010). An Olympus light microscope (Olympus DP72)
equipped with a motorized stage and a digital camera connected
to a PC was used for stereological counting. After delineation
of the graft with a 4× objective, the TH positive cells with a
clearly stained cell body were counted with a 40× objective. The
estimated cell number was calculated by the following equation
N: = (1/ssf)∗(1/asf)∗(1/hsf)∗the sum of the counts as described
by Kelsen et al. (2010). The section sample fraction (ssf) was
0.3, because every third section was used for analysis. The area
sampling fraction (asf) was set to 1 as 100% of the graft was
analyzed. The height of the sampling fraction (hsf) was 1 as the
whole section thickness of 30 µm was used. Grafts of controls
contained 547± 71 TH positive neurons (mean± SEM; n= 6).
Estimation of Remaining TH Positive Fibers in the
Striatum
One section of each rat at the following coordinate in relation
to bregma (Paxinos Watson rat brain atlas): anterior 1.5 mm
was selected to determine the remaining TH positive fiber
density in the striatum of rats that did not receive a transplant
(second experimental setup), as described previously (Seiler et al.,
2016). In brief, the striatum of the lesioned and unlesioned
side was photographed by a microscope (Olympus DP72) that
was connected to a digital camera (Olympus). The images were
converted to 8 bit black and white pictures and inverted using
the Fiji software. The mean gray intensity of the dorsal striatum
of the lesioned and unlesioned side was measured in a defined
area (100,000 µm2). To account for non-specific background
staining, the mean gray value in a defined area (30,000 mm2)
in the corpus callosum was measured. The mean gray intensity
of the corpus callosum was subtracted from the respective
striatal mean gray intensity values and then the values of the
lesioned striatum were expressed as percentage of the unlesioned
side.
Statistical Analysis
For statistical analysis a commercially available software package
was used (GraphPad Prism 7). To compare group means of
several groups repeated two-way ANOVA was used, followed
by Tukey’s or Bonferroni’s multiple comparison test where
appropriate. Statistical significance of two groups only, was
assessed by two-tailed unpaired t-test and the statistical
significance levels are expressed as tα/υ, where α indicates
the student’s t-values and υ the relative degree of freedom.
Statistical significance was set at p < 0.05. Data are presented as
mean± SEM.
RESULTS
Estimated Extent of the Lesion
The analysis of TH immunoreactive neurons in the SNc disclosed
a lesion extent of 68% ± 3.4% in the first experimental setup and
36.4% ± 6.0% in the second. No significant difference between
the three levels analyzed or between the saline and NEP1-40
treatment groups was detected.
Behavioral Analyses
Cylinder Test Experimental Set Up 1
The asymmetrical forelimb use after unilateral 6-OHDA lesion
was assessed in a cylinder. As expected, the lesioned rats
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FIGURE 4 | Effects of intra-ventricular infusion of saline or NEP1-40 on
tyrosine hydroxylase (TH) positive cell numbers in the grafts.
Representative photomicrographs of TH positive neurons (arrowheads) in the
grafts of saline (A) and NEP1-40 treated (B) rats. Scale bar: 20 µm. No
difference between the two groups could be observed, as depicted in the bar
graph (C). Data are given as mean + SEM and are presented as percentage
of saline.
scored significantly less often with the left paw (contralateral
to the lesion) compared to baseline (49.0 ± 1.2 vs. 18.4 ± 6.0,
% of left paw use for baseline and lesioned in the saline
group, t4.9/4 ≤ 0.01 and 50.6 ± 1.8 vs. 19.7 ± 5.2, % of
left paw use for baseline and lesioned in the NEP1-40 group,
t6.0/6 ≤ 0.001) (Figure 2A). No significant difference could
be found between NEP1-40 and saline treated groups (data
not shown). One week after the transplantation no significant
behavioral improvement was observed as compared to the post-
lesion time point [26.3 ± 4.6 vs. 18.4 ± 6.0 and 27.2 ± 4.8
vs. 19.7 ± 5.2; % of left paw use for saline and NEP1-40 vs.
lesioned, respectively; Time point, F(2,20) = 41.29, p < 0.0001;
post hoc, lesioned vs. saline p = 0.33 and lesioned vs. NEP1-
40 p = 0.25] (Figure 2A). In contrast, 3 weeks after the
transplantation the rats significantly increased the use of the
left paw in both treatment groups as compared to the post-
lesion time point [32.0 ± 5.1 vs. 18.4 ± 6.0 and 33.3 ± 3.1
vs. 19.7 ± 5.2; % of left paw use for saline and NEP1-40 vs.
lesioned, respectively; Time point, F(2,20) = 38.72, p < 0.0001;
post hoc, lesioned vs. saline p = 0.05 and lesioned vs. NEP1-40
p = 0.02] (Figure 2B). On the other hand, only the NEP1-
40 treated rats showed a significant constant improvement
in left paw use over the 5 weeks after transplantation as
compared to lesioned (36.8 ± 4.8 vs. 19.7 ± 5.2; % of left
paw use for NEP1-40 and lesioned, respectively; Time point,
F(2,20) = 28.19, p < 0.0001; post hoc, lesioned vs. NEP1-40
p = 0.01] (Figure 2C). In contrast, saline treated rats did not
perform significantly better 5 weeks after the transplantation
than at the post-lesion time point [26.2 ± 5.9 vs. 18.4 ± 6.0;
% of left paw use for saline and lesioned, respectively; Time
point, F(2,20) = 28.19, p < 0.0001; post hoc, lesioned vs. saline
p = 0.44] (Figure 2C). Hence, even though both treatment
groups showed a tendency for recovery, at all observed time
points all rats performed significantly worse compared to baseline
(Figures 2A–C). Moreover, the NEP1-40 treated rats never
displayed significantly better results in the behavioral test than
the saline treated rats (1Wp.T. 27.2 ± 4.8 vs. 26.3 ± 4.6; 3Wp.T.
33.3 ± 3.1 vs. 32.0 ± 5.1 and 5Wp.T. 36.8 ± 4.8 vs. 26.2 ± 5.9; %
of left paw use for NEP1-40 and saline treated rats; Treatment,
F(1,10) = 0.07; p > 0.05; post hoc, 1Wp.T. saline vs. NEP1-
40 p = 1.0; Treatment, F(1,10) = 0.12; p > 0.05; post hoc,
3Wp.T. saline vs. NEP1-40 p = 1.0; Treatment, F(1,10) = 1.01;
p > 0.05; post hoc, 5Wp.T. saline vs. NEP1-40 p = 0.34]
(Figures 2A–C).
Cylinder Test Experimental Set Up 2
The lesioned rats scored significantly less often with the left paw
(contralateral to the lesion) compared to baseline (52.8 ± 1.6
vs. 36.4 ± 3.5, % of left paw use for baseline and lesioned in
the saline group, t6.6/6 ≤ 0.01 and 48.8 ± 2.2 vs. 36.7 ± 5.5,
% of left paw use for baseline and lesioned in the NEP1-40
group, t3.2/6 ≤ 0.01) (Figure 2D). No significant difference could
be found between NEP1-40 and saline treated groups (data
not shown). Five weeks after the transplantation no significant
behavioral improvement was observed as compared to the post-
lesion time point [42.2 ± 2.7 vs. 36.4 ± 3.5 and 33.9 ± 3.4 vs.
36.7± 5.5; % of left paw use for saline and NEP1-40 vs. lesioned,
respectively; Time point, F(2,24) = 13.26, p < 0.0001; post hoc,
lesioned vs. saline p = 0.38 and lesioned vs. NEP1-40 p = 0.80]
(Figure 2D). Moreover, the rats touched the wall with the left paw
still significantly less often (Figure 2D).
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FIGURE 5 | Effects of intra-ventricular infusion of saline or NEP1-40 on tyrosine hydroxylase (TH) positive fiber outgrowth. Representative
photomicrographs of TH positive fibers from the graft growing into the host tissue (arrows) from saline (A) and NEP1-40 treated (B) animals. The black dashed line
indicates the graft boarder. Note the slight but significant increase in TH positive fibers growing 100 µm medially into the host brain resulting in a significant overall
larger TH positive fiber outgrowth into the host brain, as indicated in the bar graphs (C,D). Scale bar: 20 µm. Data are given as mean + SEM and are presented as
percentage of corresponding saline. ∗p < 0.05.
Histological Analyses
At the histological level the graft volume did not differ in both
treatment groups (88.6% ± 18.0% vs. 100% ± 14.7%; for NEP1-
40 and saline treatment, respectively; t0.48/11 = 0.64) (Figure 3).
Likewise, the content of surviving TH positive cells per graft
was similar in the two experimental groups (96.9% ± 20.9% vs.
100%± 12.9%; for NEP1-40 and saline treatment; t0.12/11 = 0.90)
(Figure 4). However, NEP1-40 treatment significantly promoted
the fiber outgrowth of transplanted TH positive neurons
into the host brain as compared to saline treatment (by
1.6-fold; t3.6/11 = 0.004). A more detailed analysis revealed
that significantly more TH positive fibers in the NEP1-40
group grew medially and laterally into the host brain as
compared to the saline group [F(1,11) = 13.24; p < 0.05;
post hoc, p < 0.001 and p < 0.01, respectively], whereas
dorsal and ventral sites did not show a significant difference
between the groups (Figure 5). In experimental setup 2 in
which rats were receiving mini osmotic pumps only, no
difference in striatal TH positive fiber densities was detected
between saline and NEP1-40 treated animals (t0.5/12 = 0.621)
(Figure 6).
DISCUSSION
This study shows that NgR1 antagonization in combination with
tissue grafts significantly promoted TH positive fiber outgrowth
into the host brain of hemi-parkinsonian rats. Moreover, over
the post transplantation period the NEP1-40 treated group
displayed a tendency for behavioral improvement, however,
this did not reach statistical significance. These observations
hint to the idea that a certain level of TH positive fibers
growing into the host brain is needed to result in behavioral
recovery. In line with this notion, our correlation analyzes
for TH positive neurons in the graft and TH positive fiber
outgrowth with asymmetrical forelimb use showed no association
(data not shown). Our results underscore the critical role of
the number of surviving TH positive neurons in the grafts for
the improvement of the behavioral deficits within the frame
of the experimental conditions described here (Brundin et al.,
1988; Meyer et al., 1998). The only partial functional recovery
observed in the saline treated control rats grafted with half a
VM was expected and purposely chosen to allow monitoring
of the efficacy of the NEP1-40 treatment (Meyer et al., 1998;
Frontiers in Cellular Neuroscience | www.frontiersin.org 8 May 2017 | Volume 11 | Article 151
fncel-11-00151 May 24, 2017 Time: 16:38 # 9
Seiler et al. NEP1-40 Enhances Grafted Fiber Outgrowth
FIGURE 6 | Effects of intra-ventricular infusion of saline or NEP1-40 on
striatal tyrosine hydroxylase (TH) positive fiber density. Representative
photomicrographs of TH positive fiber densities in the striatum from saline (A)
and NEP1-40 (B) treated animals. No difference in striatal TH positive fiber
density was detected between the two groups (C). Scale bar: 100 µm. Data
are given as mean + SEM and are presented as percentage of saline.
Seiler et al., 2016). The lack of effect of NEP1-40 treatment on
the TH cell number in the transplants and on the graft volume
is, however, in contrast to our previous work, demonstrating
an increase in volume and number of TH positive cells in
VM free-floating roller tube cultures (Seiler et al., 2013). This
difference might depend on the actual concentration of NEP1-
40 reaching the VM tissue. While in the culture system the
NEP1-40 concentration is defined and stable, NEP1-40 infused
into the lateral ventricle is likely diluted in the CSF given
the continuous turnover of the CSF (3.4 l/min (Redzic et al.,
2005)). NEP1-40 does diffuse from the CSF into the brain
parenchyma as several studies have shown (Fang et al., 2010;
Wang et al., 2012). The observation that the effects of NEP1-40
treatment on TH positive fiber outgrowth was most prominent
toward the ventricle further support these findings. Nevertheless,
the effects of NEP1-40 on VM tissue grafts in our study
might have been underestimated, even though we have used
a concentration as previously described (Wang et al., 2012),
and further studies using higher concentrations of NEP1-40 are
needed. Given that in our experimental model the striatum is
not completely denervated by 6-OHDA and NEP1-40 penetrates
into the parenchyma, we next reasoned whether NEP1-40 might
target the spared TH fibers. In experimental setup 2 we tested
for that hypothesis. In our measurements of TH positive fiber
densities, however, we found no evidence that NEP1-40 exerts
effect on TH fiber densities in absence of a graft. Importantly
to note, we cannot exclude that NEP1-40 treatment exerts other
effects on the brain, such as for example on microglia (Fang et al.,
2015).
These results complement our previous findings gathered
using the same experimental setup investigating the potential of
inhibition of Nogo-A/NgR1 signaling by means of ventricular
infusion of neutralizing Nogo-A antibodies (Seiler et al., 2016).
So, we reported that anti-Nogo-A antibody treated rats gradually
improved their performance in the cylinder test, reaching almost
baseline levels 5 weeks after the transplantation (Seiler et al.,
2016). In this respect it is important to note that NEP1-40
treatment seems to have a substantially lower capacity to support
graft function. We hypothesize that the different signaling
partners and mechanisms activated by Nogo-neutralization and
by its receptor antagonization might account, at least in part,
for the dissimilar effects observed in the two distinct studies.
In fact, the neutralizing anti-Nogo-A antibodies used in the
previous work targeted the 1-20 domain of Nogo-A, which
is known to bind to the sphingosine-1 phosphate receptor 2
(S1PR2) but not to the NgR1 (Akbik et al., 2012; Kurowska
et al., 2014; Saha et al., 2014). Hence, functional recovery
and increased TH positive fiber outgrowth after anti-Nogo-A
antibody infusion in our previous study was observed even
though the Nogo-A-NgR1 pathway was still active. Given that
the NgR1 does not only bind Nogo-A through its Nogo-
66 domain, but also other growth inhibitors such as myelin
associated glycoprotein, the oligodendrocyte myelin glycoprotein
and the chondroitin sulfate proteoglycans (Akbik et al., 2012;
Schwab and Strittmatter, 2014), it was tempting to speculate that
antagonization of the NgR1 might be more potent in enhancing
graft function and TH positive fiber outgrowth than inhibiting
specifically Nogo-A. The results of the present study, however,
did not support this notion even though the above mentioned
issues need to be addressed in more depth to draw a final
conclusion.
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CONCLUSION
In sum, the present study demonstrates that NEP1-40 treatment
of hemi-parkinsonian rats promoted TH positive fiber outgrowth
into the host brain which, however, was not sufficient to induce
functional recovery to baseline levels. In line with the latter
observation NEP1-40 treatment did not enhance graft volume
or survival of transplanted dopaminergic neurons. Alternative
strategies to inhibit Nogo-A signaling as for example through
neutralizing anti-Nogo-A antibodies possibly in combination
with application of neurotrophic factors should be considered to
enhance engraftment and function of the transplant.
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